MedTrace Logo

Gemcitabine and S-1 for Advanced Biliary Tract Cancer

NCT02146703 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2014-05-26

No results posted yet for this study

Summary

This study will conduct a phase II study of gemcitabine and S-1 as first-line chemotherapy in patient with advanced biliary tract cancer

Conditions

  • Biliary Tract Neoplasm

Interventions

DRUG

Gemcitabine, and S-1

Treatment will be delivered as a 3-week cycle. 1. Gemcitabine 1000 mg/m2 iv on day 1, 8 2. S-1 60 mg/day po on day 1-14

Sponsors & Collaborators

  • Jeil Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Hallym University Medical Center

    lead OTHER

Principal Investigators

  • Dae Young Zang, MD, PhD · Hallym University Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2010-11-30
Completion
2013-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02146703 on ClinicalTrials.gov